Keyphrases
Relapsed or Refractory
100%
Follicular Lymphoma
100%
Axicabtagene Ciloleucel
100%
Cell-to-cell
20%
T Cells
20%
Cell Therapy
20%
Chimeric Antigen Receptor T Cells (CAR-T)
20%
Poor Clinical Outcomes
20%
Durable Response
20%
Safety Data
20%
Phase II Trial
20%
Anti-CD20 Antibody
20%
Alkylating Agents
20%
Heavily Pretreated Patients
20%
Expert Opinion
20%
Indolent non-Hodgkin Lymphoma
20%
Line of Therapy
20%
Efficacy Data
20%
Toxicity Profile
20%
Safety Self-efficacy
20%
Area Cover
20%
Chimeric Antigen Receptor T-cell Therapy
20%
Anti-CD19 chimeric Antigen Receptor T Cells
20%
Pharmacokinetic Data
20%
5-Phases
20%
Drug Profile
20%
Medicine and Dentistry
Follicular Lymphoma
100%
Axicabtagene Ciloleucel
100%
T Cell
20%
Non-Hodgkin Lymphoma
20%
Rituximab
20%
Alkylating Antineoplastic Agent
20%
Cell Therapy
20%
Pharmacokinetics
20%
Phase II Trials
20%
Chimeric Antigen Receptor T-Cell
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Drug Analysis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Follicular Lymphoma
100%
Axicabtagene Ciloleucel
100%
Chimeric Antigen Receptor
40%
Nonhodgkin Lymphoma
20%
Rituximab
20%
Phase II Trials
20%
Alkylating Agent
20%
Pharmacokinetics
20%